Pancreatic Cell News Volume 1.30 | Nov 16 2010

    By
    Justin.choi
    -
    0
    32

    Pancreatic Cell News 1.30, November 16, 2010.
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events | 

    TOP STORY 

    Reversal of Preexisting Hyperglycemia in Diabetic Mice by Acute Deletion of the Men1 Gene  ShareThis
    Men1 excision improved glucose metabolism at least partly through increasing proliferation of endogenous beta cells and islet size. [Proc Natl Acad Sci U S A ]

    EasySep_645x110_v01

    SPECIAL FEATURES 

    Interested in recruiting talented individuals? Post your career opportunities in Pancreatic Cell News at no cost. Contact us at info@connexoncreative.com

    Follow us on Twitter! @PancreaticCell

    SCIENCE NEWS

    Dietary Changes May Prevent Autoimmunity That Leads to Type 1 Diabetes in At-Risk Babies
    Changing the diets of babies with high genetic risk for type 1 diabetes protected them from developing the autoimmunity that destroys insulin-producing cells over the first ten years of life. [Press release from The Hospital for Sick Children discussing online prepublication in the New England Journal of Medicine]
     
    Geron Announces Publications Demonstrating That Its Telomerase Inhibitor Drug Targets Cancer Stem Cells
    Researchers demonstrate the inhibitory effect of imetelstat on cancer stem cells from breast and pancreatic tumor cell lines in vitro and in animal models of the human disease. [Press release from Geron Corporation discussing online prepublication in Cancer Research]

    Request a Sample 
    Fast Isolation of Functional Human Regulatory T Cells
    with EasySep®
    		 
     
    REQUEST A SAMPLESTEMCELL Technologies Inc
    		 

    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    DIABETES

    Dietary Intervention in Infancy and Later Signs of Beta Cell Autoimmunity
    Dietary intervention during infancy appears to have a long-lasting effect on markers of beta cell autoimmunity — markers that may reflect an autoimmune process leading to type 1 diabetes. [N Engl J Med]
     
    Three-Amino-Acid-Loop-Extension Homeodomain Factor Meis3 Regulates Cell Survival via PDK1
    Researchers show that Meis3 is abundantly expressed in pancreatic islets and beta cells and that it regulates beta cell survival. They further identify the 3-phosphoinositide-dependent protein kinase 1 (PDK1) as a direct Meis3 target, which mediates its role in beta cell survival. [Proc Natl Acad Sci U S A]
     
    M3 -Muscarinic Receptor Promotes Insulin Release via Receptor Phosphorylation/Arrestin-Dependent Activation of Protein Kinase D1
    Findings support the unique concept that M3-muscarinic receptor-mediated augmentation of sustained insulin release is largely independent of G protein-coupling but involves phosphorylation-/arrestin-dependent coupling of the receptor to protein kinase D1. [Proc Natl Acad Sci U S A]
     
    Translationally Controlled Tumor Protein (TCTP) Is a Novel Glucose-Regulated Protein That Is Important for Survival of Pancreatic Beta Cells
    Results imply that TCTP levels influence the sensitivity of beta cells to apoptosis. [Diabetologia]
     
    Conditional Expression of the FTO Gene Product in Rat INS-1 Cells Reveals Its Rapid Turnover and a Role in the Profile of Glucose-Induced Insulin Secretion
    Data suggest that the fat mass and obesity associated (FTO) protein may play a hitherto unrecognized role in the control of first phase insulin secretion in pancreatic beta cells. [Clin Sci]
     
    Spontaneous In Vivo Differentiation of Embryonic Stem Cell-Derived Pancreatic Endoderm-Like Cells Corrects Hyperglycemia in Diabetic Mice
    Data suggest that Pdx1-expressing pancreatic endoderm-like cells are capable of spontaneously undergoing differentiation in vivo into insulin-producing cells and leading to a sustained correction of hyperglycemia in diabetic mice. [Transplantation]
     
    Transforming Growth Factor (TGF)-Beta Induces Epithelial to Mesenchymal Transition and Suppresses the Proliferation and Transdifferentiation of Cultured Human Pancreatic Duct Cells
    Results are the first report of TGF-beta1 effects for epithelial to mesenchymal transition and ductal cell transdifferentiation and proliferation at the protein level in human pancreatic duct cells. [J Cell Biochem]

    PANCREATIC CANCER

    The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines
    Researchers investigated the effects of imetelstat (GRN163L), a potent telomerase inhibitor, on both the bulk cancer cells and putative cancer stem cells (CSCs). When breast and pancreatic cancer cell lines were treated with imetelstat in vitro, telomerase activity in the bulk tumor cells and CSC subpopulations were inhibited. [Cancer Res]
     
    A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
    Results identify a novel 3p pathway associated migration signature and plasma biomarker panel that has utility for discrimination of pancreatic cancer from normal controls and promise for clinical application. [Cancer Prev Res]
     
    Cytotoxic Responses to N-(4-Hydroxyphenyl) Retinamide in Human Pancreatic Cancer Cells
    Data show that fenretinide triggers pancreatic cancer cell death by apoptosis and autophagy and that sensitivity appears to be mediated by reactive oxygen species and not ceramide. [Cancer Chemother Pharmacol]

    INDUSTRY NEWS

    Clavis Pharma and Clovis Oncology Extend Partnership and Sign New $205 Million Deal for the Development and Commercialization of Anti-Cancer Agent CP-4126 in Asia and Rest of the World
    Clavis Pharma ASA and Clovis Oncology, Inc. announced a new agreement for the further development and commercialization of CP-4126 (also known as CO-101), which is currently in Phase II development in pancreatic cancer. [Clavis Pharma Press Release]
     
    London Genetics and Astrimmune to Find Predictive Biomarkers for Pancreatic Cancer Vaccine
    London Genetics and Astrimmune will work together to establish a biomarker identification program for the latter’s pancreatic cancer vaccine candidate. [Genetic Engineering and Biotechnology News]
     
    Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America’s Type 2 Diabetes Crisis
    The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America’s Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor’s office — in their homes and communities — and for the course of their disease. [Bristol-Myers Squibb Foundation Press Release]

    Xoma Issued Two New U.S. Patents Covering XOMA 052
    Xoma Ltd. announced that the U.S. Patent and Trademark Office issued two new patents to Xoma as part of the company’s expanding intellectual property portfolio around its XOMA 052 antibody to interleukin-1 beta. [Xoma Ltd. Press Release]
     
    Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting
    Access Pharmaceuticals, Inc. announced that it presented a poster at the 10th Annual Diabetes Technology Meeting, entitled, “Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin.” [Access Pharmaceuticals, Inc. Press Release]

    Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
    Scientists from Biodel Inc. reported new findings from the company’s Linjeta™, insulin glargine, “smart” basal insulin and stabilized glucagon development programs in poster presentations at the 10th Annual Diabetes Technology Meeting in Bethesda, MD. [Biodel Inc. Press Release]
     
    Halozyme’s rHuPH20 with Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
    Halozyme Therapeutics, Inc. announced Phase II results demonstrating that Insulin-PH20 (recombinant human insulin with rHuPH20) produced glycemic control comparable to lispro. [Halozyme Therapeutics, Inc. Press Release]
     
    Biomedical Warp Knit Project Aids Diabetes Research
    Narrow fabrics machinery manufacturer Comez has developed an innovative electronic double needle bar warp knitting machine for use in an Italian regional government funded biomedical textiles project. The Panagenesi project aims to help cure diabetes by optimizing the implanting of human pancreatic islands through the use of fibrin scaffold to aid in the success of pancreatic transplants. [Knitting Industry]
     
    Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2010
    Boston Scientific Corporation announced its sponsorship of “World Diabetes Day” for the third year in a row.  The campaign is led by the International Diabetes Federation and represents its primary global awareness initiative in the fight against diabetes. [Boston Scientific Corporation Press Release]

    POLICY NEWS

    Australia Shelves $450 Million Diabetes Care Plan
    The federal government has shelved its controversial diabetes reform plan that was meant to allow patients to sign up with a “home” GP practice for continuing care from mid-2012. [Ministry of Health, Australia]

    Juvenile Diabetes Research Foundation Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing
    Diabetes experts at a meeting convened by the U.S. Food and Drug Administration and the National Institutes of Health took the next step in advancing efforts toward the development of an artificial pancreas: putting forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations. [Juvenile Diabetes Research Foundation, United States]
     
    FDA Seen Tougher on Drug Risks Post-Avandia
    Regulators appear to be increasing their scrutiny of product risks after cases like the bitter debate over the diabetes pill Avandia, industry executives and experts said. [Food and Drug Administration, United States]

    National Institutes of Health (United States)

    Food and Drug Administration (United States)
     
    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)
     
    Medicines and Healthcare Products Regulatory Agency (United Kingdom)
     
    Therapeutic Goods Administration (Australia)

    EVENTS (Listed by Date)

    Pharmacology in Stem Cells Research and Regenerative Medicine
    December 17, 2010
    London, United Kingdom

    NEW The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
    December 17-19, 2010
    Guangzhou, China

    Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction
    January 12-17, 2011
    Dillon, United States

    Keystone Symposia: Obesity
    January 12-17, 2011
    Keystone, United States

    2011 Gastrointestinal Cancers Symposium
    January 20-22, 2011
    San Francisco, United States

    Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
    January 21-26, 2011
    Vancouver, Canada

    5th Annual Stem Cells and Regenerative Medicine World Congress
    January 24-25, 2011
    San Diego, United States

    Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
    January 24-26, 2011
    Washington, D.C., United States

    Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference
    January 26-27, 2011
    Amsterdam, The Netherlands

    Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club
    February 10-13, 2011
    Maradu, India

    NEW 2nd Annual International Diabetes Summit
    February 22-24, 2011
    Dubai, United Arab Emirates

    United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
    March 30-April 1, 2011
    York, United Kingdom

    American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
    April 2-6, 2011
    Orlando, United States

    13th Annual C21 BioVentures
    May 24-26, 2011
    Napa, United States

    European Pancreatic Club Meeting 2011
    June 22-25, 2011
    Magdeburg, Germany

    PancreasFest 2011
    July 28-30, 2011
    Pittsburgh, United States

    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

     


    JOB OPPORTUNITIES

    Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

    Lab Technologist – Tissue Culture (STEMCELL Technologies)

    Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)


    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

    Visit     here  to post your career opportunities.


    Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

     
    forwardafriendicon
     
    Comments or Suggestions? Email info@connexoncreative.com with your feedback.



    Learn more about Pancreatic Cell News: Archives | Events | Contact Us